Aptevo Therapeutics completes 1-for-37 reverse stock split effective December 3, 2024

Aptevo Therapeutics Inc.

Certificate of Amendment filed with Delaware; split effective at 5:01 p.m. ET on December 3, 2024.
Every 37 pre-split shares combined into one share; par value unchanged; no fractional shares issued.
Trading on Nasdaq Capital Market begins on split-adjusted basis December 4, 2024; new CUSIP 03835L 405.
Proportionate adjustments made to stock options, RSUs, warrants, and equity plan reserves.
Stockholders' percentage ownership unchanged except for fractional share cash payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.